Robust production of type I interferon (IFN-a/b) in plasmacytoid dendritic cells (pDCs) is crucial for antiviral immunity. Here we show involvement of the mammalian target of rapamycin (mTOR) pathway in regulating interferon production by pDCs. Inhibition of mTOR or its 'downstream' mediators, the p70 ribosomal S6 protein kinases p70S6K1 and p70S6K2, during pDC activation by Toll-like receptor 9 (TLR9) blocked the interaction of TLR9 with the adaptor MyD88 and subsequent activation of the interferon-regulatory factor IRF7, which resulted in impaired IFN-a/b production. Microarray analysis confirmed that inhibition of mTOR by the immunosuppressive drug rapamycin suppressed antiviral and anti-inflammatory gene expression. Consistent with this, targeting rapamycin-encapsulated microparticles to antigen-presenting cells in vivo resulted in less IFN-a/b production in response to CpG DNA or the yellow fever vaccine virus strain 17D. Thus, mTOR signaling is crucial in TLR-mediated IFN-a/b responses by pDCs.
Plasmacytoid dendritic cells (pDCs) are specialized immune cells able to rapidly produce large amounts of type I interferon for antiviral innate immunity [1] [2] [3] . Induction of the antiviral innate immune response depends on recognition of viral components by Toll-like receptors (TLRs) 4 . The pDCs 'preferentially' express virus-recognizing TLR7 and TLR9, which sense viral single-stranded RNA and unmethylated CpG-rich DNA, respectively 5 . 'Downstream' of TLR7 and TLR9 engagement, interferon production by pDCs depends absolutely on the adaptor protein MyD88-interferon-regulatory protein IRF7 signaling pathway 6, 7 . Data have shown that phosphatidylinositol-3-OH kinase (PI(3)K)-Akt kinase activity influences TLR-induced cytokine production in myeloid DCs 8 . The kinase mTOR (mammalian target of rapamycin) is a crucial 'downstream' mediator of PI(3)K-Akt signaling and a key regulator of cell growth and proliferation [9] [10] [11] . Increasing evidence suggests that mTOR integrates signals from nutrients, energy status and growth factors to regulate many processes, including autophagy, ribosome biogenesis and metabolism [9] [10] [11] . It has been found that mTOR also is important in the survival and maturation of myeloid DCs 12 , which suggests there is crosstalk between TLR signaling and the PI(3)K-Akt-mTOR pathway. However, it is unclear whether mTOR influences the function of pDCs.
Here we show that the rapamycin-sensitive PI(3)K-mTOR-p70 ribosomal S6 protein kinase (p70S6K) pathway is crucial for TLRmediated induction of type I interferon in pDCs. Inhibition of mTOR or p70S6K by various approaches resulted in much less TLR-mediated production of interferon-a (IFN-a) by pDCs. The mechanism of this inhibition seemed to involve disruption of the TLR9-MyD88 complex and subsequent impairment of phosphorylation and nuclear translocation of IRF7. A physiological function for the mTOR pathway in regulating IFN-a production was emphasized by the finding that mTOR inhibition in vivo resulted in less IFN-a in serum and in pDCs in response to stimulation with a TLR ligand or viral vaccine, which ultimately led to impaired immune responses.
RESULTS

Rapamycin inhibits TLR-mediated IFN-a production by pDCs
To assess the involvement of mTOR in pDC function, we used the highly specific mTOR inhibitor rapamycin 13 . We stimulated purified human and mouse pDCs with the TLR9 ligand A-D-type CpG oligodeoxynucleotide (CpG-A; ODN 2336) 14 in the presence of rapamycin or with vehicle alone. Rapamycin, even at low nanomolar concentrations, substantially suppressed CpG-A-induced IFN-a production by both mouse and human pDCs (Fig. 1a) . In addition to IFN-a, activated pDCs secrete IFN-b and moderate amounts of other proinflammatory cytokines, including tumor necrosis factor (TNF) and interleukin 6 (IL-6). Rapamycin also significantly inhibited pDC secretion of IFN-b, TNF and IL-6 ( Fig. 1b and Supplementary Fig. 1 online). In contrast, production of CXCL10 (IP-10) was induced by CpG but was not suppressed by rapamycin. The inhibitory effect of rapamycin on IFN-a production was not limited to TLR9 stimulation, as rapamycin also impaired IFN-a production induced by the TLR7 ligand loxoribine and several viruses, including the yellow fever vaccine strain 17D (YF-17D) and vesicular stomatitis virus (Fig. 1c) . To exclude the possibility that these effects were caused simply by a decrease in pDC numbers through apoptosis, we examined the apoptotic sensitivity of pDCs to mTOR inhibition. Rapamycin, even at high concentrations, did not induce apoptosis of pDCs, as shown by labeling with annexin V and propidium iodide (Fig. 1d) .
To determine the effect of rapamycin on other DC subsets, we analyzed mouse bone marrow-derived DCs and human monocytederived DCs as described above. In both types of DCs, there was substantial diminution of IL-10, IL-6 and TNF production when cells were treated with rapamycin before begin activated with lipopolysaccharide (LPS; Supplementary Fig. 2 online) . In contrast, IL-12p40 production in mouse bone marrow-derived DCs and IL-12p70 production in human monocyte-derived DCs were not affected by rapamycin pretreatment (Supplementary Fig. 2 ). In addition to rapamycin, cyclosporin A (CsA) and FK506 (tacrolimus) are two other commonly used immunosuppressive drugs. FK506 has structural similarity to rapamycin and even forms a complex with the same FK506 binding proteins 15 . Both CsA and FK506 bind to and inhibit calcineurin in a calcium-dependent signaling pathway 16 . CsA and FK506 had different effects on cytokine production by bone marrowand monocyte-derived DCs than did rapamycin. CsA and FK506 considerably suppressed IL-12p70 production but had no effect on the production of IL-12p40, IL-10, IL-6 and TNF by LPS-activated bone marrow-derived DCs and monocyte-derived DCs ( Supplementary  Fig. 2) . Collectively, these data show that inhibition of mTOR suppresses IFN-a/b production by pDCs after microbial stimulation.
Given that rapamycin suppressed the TLR-mediated innate responses of pDCs, we determined whether rapamycin-treated pDCs were compromised in their ability to stimulate T cell responses. We used an in vitro antigen presentation assay in which we cultured pDCs with ovalbumin, CpG-A and OT-II CD4 + T cells, which express a transgenic T cell receptor specific for ovalbumin peptide presented by major histocompatibility complex class II molecules. After 3 d of culture, we assessed the proliferation of OT-II T cells through their incorporation of tritiated thymidine and measured the induction of IFN-g, IL-4, IL-10, IL-13 and IL-17 by enzyme-linked immunosorbent assay (ELISA). The pDCs pulsed with CpG-A and ovalbumin induced robust OT-II T-cell proliferation; in contrast, rapamycin-pretreated pDCs showed a reduced immune-stimulatory capacity (Fig. 1e) .
We next assessed cytokine production by the OT-II cell cultures described above. In cultures from vehicle-treated pDCs, we detected large amounts of IFN-g, IL-17, IL-10, IL-4 and IL-13; in contrast, rapamycin-pretreated pDCs had much lower expression of IFN-g, IL-17 and IL-10 and had slightly lower expression of the T helper type 2 (T H 2) cytokines IL-4 and IL-13. These data indicate that rapamycintreated pDCs are impaired in their ability to stimulate antigen-specific CD4 + T cell activation in vitro, consistent with a published study 17 .
TLR stimulation of pDCs activates the mTOR pathway To assess the mechanism by which rapamycin inhibits TLR-mediated interferon production by pDCs, we examined the activation of mTOR by detecting its phosphorylated form with a specific antibody to phosphorylated mTOR. CpG-A strongly induced phosphorylation of mTOR in the RAW264.7 mouse macrophage cell line within 15 min and for at least 1 h; rapamycin pretreatment inhibited the effect of CpG-A at all time points tested (Fig. 2a) . Unexpectedly, in pDCs, we found constitutive phosphorylation of mTOR (at the serine at position 2448 (Ser2448)) even in the absence of stimulation with CpG-A, although pretreatment of pDCs with rapamycin inhibited mTOR phosphorylation (Fig. 2b) .
Phosphorylation of mTOR leads to more phosphorylation and inactivation of the repressor of mRNA translation 4E-BP1 (eukaryotic initiation factor 4E-binding protein). Phosphorylation of mTOR also leads to activation of p70S6K, which enhances protein translation [9] [10] [11] [12] [18] [19] [20] [21] . It has been shown that mTOR, p70S6K and 4E-BP1 are all 'downstream' phosphorylation targets of the kinase Akt 22 . As with mTOR, p70S6K and Akt were constitutively phosphorylated in freshly isolated pDCs (Fig. 2b) . Stimulation of pDCs with CpG-A resulted in a slight, yet rapid, enhancement of p70S6K phosphorylation at 5 min, which decreased to constitutive baseline by 15 min (data not shown), and a more substantial enhancement of 4E-BP1 phosphorylation. Pretreatment of pDCs with rapamycin inhibited the phosphorylation of p70S6K at Thr389. Initially, rapamycin did not seem to affect the phosphorylation of 4E-BP1 at Thr37, Thr46 or Thr70 much, although it did diminish phosphorylation at Ser65 (Fig. 2b) ; however, exposure to rapamycin for 6 h or longer did result in inhibition of phosphorylation at Thr70 (data not shown). The total amounts of mTOR, p70S6K and 4E-BP1 protein were not altered much by rapamycin.
TLR induction of IFN-a requires the mTOR pathway
We next determined the functional consequences of disrupting the mTOR pathway in pDCs. Knockdown of mTOR in pDCs by small interfering RNA (siRNA) suppressed IFN-a production after CpG-A stimulation ( Fig. 3a) , consistent with the inhibitory effect of rapamycin on IFN-a production. Pretreatment of cells with LY294002, a specific inhibitor of PI(3)K (an 'upstream' mediator of mTOR 21 ), also considerably suppressed CpG-A-induced IFN-a secretion in pDCs in a dose-dependent way (Fig. 3b) . This indicated that the PI(3)K-mTOR pathway is crucial for CpG-A-induced production of IFN-a in pDCs.
Phospho-Akt Deletion of 4E-BP1 and 4E-BP2 has been shown to enhance the production of type I interferon in pDCs through translational control of IRF7 mRNA 23 . However, it is not clear whether p70S6K also regulates IFN-a production in pDCs. We therefore evaluated the function of p70S6K in this process. We transfected purified pDCs with siRNA pools specific for only p70S6K1 or p70S6K2 mRNA or with siRNA pools specific for both. We confirmed the efficacy of the siRNA in 'knocking down' gene expression by measuring protein (Fig. 3c) . Downregulation of p70S6K1 (Rps6kb1) or p70S6K2 (Rps6kb2) by siRNA resulted in less IFN-a secretion by mouse pDCs (Fig. 3c) ; knockdown of both kinases resulted in even less secretion of IFN-a (Fig. 3c) . Consistent with those findings, there was less IFN-a secretion by pDCs isolated from Rps6k1 -/-Rps6k2 -/-double-knockout mice (Fig. 3d) . However, the spleens of the double-knockout mice did not have fewer pDCs ( Supplementary Fig. 3 online) . These results collectively show that CpG-A-induced IFN-a production in pDCs is mediated by the PI(3)K-mTOR-p70S6K signaling pathway.
Blocking TLR9-MyD88 interaction and IRF7 phosphorylation To further understand the mechanism of action of rapamycin in its inhibition of IFN-a in pDCs, we first assessed by flow cytometry the intracellular expression of TLR9 in rapamycin-treated pDCs. TLR9 was constitutively expressed in pDCs, and there was no substantial difference in TLR9 expression by CpG-A-activated pDCs and resting pDCs (Fig. 4a) . Rapamycin did not alter pDC TLR9 expression. The mechanism by which rapamycin inhibits IFN-a production therefore probably does not involve less expression of TLR9. Stimulation of DCs with CpG causes both TLR9 and MyD88 to be rapidly redistributed toward sites of CpG accumulation 24 . To address whether rapamycin treatment affected TLR9 redistribution and its subsequent binding to CpG, we exposed RAW cells expressing yellow fluorescent protein (YFP)-tagged TLR9 to indodicarbocyanine-tagged CpG-A and examined the localization of TLR9 and CpG-A by confocal microscopy. Rapamycin did not seem to affect the association of TLR9 with CpG-A (Fig. 4b) .
TLR9 signaling results in MyD88-dependent activation of IRF7 and the adaptor protein TRAF6, which together mediate IFN-a production 7, 25 . We further evaluated the effect of rapamycin on this signaling pathway in RAW cells, which express type I interferons. We stimulated RAW cells coexpressing YFP-tagged TLR9 and hemagglutinin-tagged MyD88 with the cationic lipid DOTAP (CpG-A-DOTAP) 7 to activate the TLR9-MyD88-IRF7 signaling pathway. We then lysed the cells, immunoprecipitated equal amounts of proteins with antibody to hemagglutinin (anti-hemagglutinin) and used immunoblot analysis to detect TLR9. TLR9 immunoprecipitated together with MyD88 after stimulation with CpG-A-DOTAP; this interaction was prevented by rapamycin (Fig. 5a) . We further verified the interaction between TLR9 and MyD88 using various expression constructs and by converse experiments in which we immunoprecipitated TLR9-MyD88 complexes with anti-TLR9 and then detected them with anti-MyD88 ( Supplementary Fig. 4 online and data not shown). In each of these cases, rapamycin inhibited the formation of TLR9-MyD88 complexes; consistent with this, siRNA knockdown of p70S6K1 and p70S6K2 also impaired TLR9-MyD88 interaction ( Supplementary Fig. 4 ). IRF7 regulates type I interferon-dependent immune responses 6 . Central to the activation of IRF7 is its phosphorylation, which leads to the formation of homodimers of IRF7 and nuclear accumulation of dimers that are able to bind DNA and transactivate interferon target genes 26, 27 . To study the effect of rapamycin on the function of IRF7, we pretreated purified human pDCs for 3 h with rapamycin and then with CpG-A. We then detected phosphorylation of IRF7 in pDCs with an antibody to IRF7 phosphorylated at Ser477 and Ser479. In the absence of rapamycin, CpG-A activation of pDCs led to phosphorylation of IRF7; phosphorylation was inhibited by rapamycin treatment, although total IRF7 protein expression was unaffected ( Fig. 5b and Supplementary Fig. 5 online) . Similarly, knockdown of p70S6K1 and p70S6K2 with specific siRNA pools resulted in less IRF7 phosphorylation (Fig. 5b) . Moreover, activation with CpG-A for 12 h led to IRF7 localization mainly in the nucleus in most isolated pDCs; this nuclear translocation of IRF7 was inhibited by pretreatment with rapamycin (Fig. 5c) . We also overexpressed a constitutively active form of IRF7 in human embryonic kidney (HEK293) cells before CpG-A stimulation and found that this 'rescued' the defect in interferon production after mTOR inhibition (Fig. 5d) . These results indicate that rapamycin inhibits the activation and nuclear translocation of IRF7 in pDCs.
We next used microarray to analyze gene expression in sorted mouse pDCs to obtain further insights into the mechanism by which rapamycin inhibited IFN-a induction in pDCs. After CpG-A stimulation for 4 or 12 h, pDCs had higher expression of genes encoding several antiviral proteins (such as IFN-a4, IFN-b1 and the interferon-inducible proteins IFI44 and IFI202B) and inflammatory molecules, including the complement proteins C5AR1 and C3, as well as several chemokines (CCL2, CCL7, CCL8 and CCL12) and chemokine receptors (CCR3). In the presence of rapamycin, expression of the genes encoding these proteins was lower, whereas the expression of genes encoding other proteins, such as CXCL10, CD86, IL-12B and IL-8RB, was either not lower or was actually higher in the presence of rapamycin ( Supplementary Fig. 6 online) .
In vivo targeting of rapamycin
To determine whether rapamycin inhibited type I interferon production in vivo, we injected rapamycin into C57BL/6 mice and, after 3 d, injected CpG-A or live attenuated YF-17D. YF-17D, one of the most effective vaccines 28 , induces immune signaling through many TLRs, including TLR2, TLR7, TLR8 and TLR9 (ref. 29) . We used ELISA to measure the kinetics of serum production of IFN-a and IFN-a produced by pDCs isolated and cultured ex vivo. Injection of CpG-A induced robust IFN-a production in pDCs 12 h after stimulation, which decreased slowly over 48 h ( Supplementary Fig. 7 online) . YF-17D-activated secretion of IFN-a had similar kinetics, and pretreatment with rapamycin resulted in significantly less IFN-a (Fig. 6a) . In contrast to the robust CpG-A-mediated induction of IFN-a in pDCs, we detected no IFN-a in the serum of CpG-A-induced mice at any time points tested ( Supplementary Fig. 7 ). However, we did detect robust serum IFN-a secretion in response to YF-17D, which peaked at 12 h and decreased to baseline at 24 h; the administration of rapamycin before YF-17D challenge inhibited serum IFN-a production (Fig. 6a) . Knockdown of p70S6K1 and p70S6K2 in pDCs inhibited the production of IFN-a in response to YF-17D in vitro ( Supplementary Fig. 8 online) , which supported our data obtained with rapamycin (Fig. 1c) . These results indicate that rapamycin potently inhibits the secretion of IFN-a in pDCs in vivo in response to CpG-A and YF-17D.
Because soluble rapamycin targets all cells in vivo and therefore would not have a specific inhibitory effect on DCs 16 , we encapsulated rapamycin in poly(lactic-co-glycolic) acid (PLGA) microparticles 30 and injected these into mice intraperitoneally to specifically enhance uptake of rapamycin by antigen-presenting cells (APCs). Published work has shown that PLGA microparticles can enhance the delivery of encapsulated molecules to APCs 30 , and our initial results confirmed that (Fig. 6b) . Additional experiments showed that pDCs from mice treated with PLGA-encapsulated rapamycin secreted much less IFN-a both after infection with YF-17D and after systemic administration of CpG-A (Fig. 6a and Supplementary Fig. 7) .
To investigate the effects of rapamycin delivery to APCs on T cell responses in vivo, we immunized mice with YF-17D and analyzed the antigen-specific CD8 + T cell response in the draining lymph nodes. We prepared single-cell suspensions of lymph nodes 5 d later and restimulated for 72 h in vitro with a combination of yellow fever CD8 + T cell epitope peptides from NS3 and E-1 (ref. 29) . We then evaluated the induction of IFN-g, IL-17, IL-4, IL-13 and IL-10 (T H 1, T H 2 and IL-17-producing T helper cell cytokines) in culture by ELISA and intracellular flow cytometry. YF-17D induced IFN-g production as measured in total cell culture supernatants and in CD8 + T cells (Fig. 7) . YF-17D also induced the production of T H 2 cytokines IL-4, IL-13 and IL-10, consistent with a published report that YF-17D induces a mixed T H 1 and T H 2 T cell response in vivo 29 . IL-17 production was also induced by in vivo YF-17D stimulation.
In vivo administration of PLGA-encapsulated rapamycin before virus challenge inhibited T H 1, T H 2 and L-17-producing T helper cell cytokines. Collectively, these findings show that mTOR inhibition in APCs in vivo can suppress the adaptive immune response to a vaccine.
DISCUSSION
It is well established that engagement of TLRs by many viruses stimulates robust production of type I interferon in pDCs, but the molecular mechanisms that regulate this important antiviral response are not fully understood. Given the crucial function of type I interferons in innate and adaptive immunity, the interferon response must be under tight control to prevent pathogenic responses. Many regulatory mechanisms involving surface receptors (BDCA2, ILT7, Siglec-H, immunoglobulin E receptor and NKp44), intracellular and exogenous factors (IRF4), and virus-encoded molecules have been shown to modulate the interferon responses of pDCs [1] [2] [3] . Osteopontin is reported to be essential for TLR9-dependent interferon production by pDCs 31 . Here we have shown that mTOR has a crucial function in the TLR-mediated induction of IFN-a in pDCs, in vitro and in vivo.
Using several independent methods to investigate whether the mTOR signaling pathway regulates type I interferon activity, we found that inhibition of mTOR-p70S6K resulted in inhibition of IRF7 phosphorylation and nuclear localization, which impaired the production of type I interferon. Several aspects of our study warrant further comment. The first relates to the mechanism by which rapamycin inhibits TLR-mediated IFN-a production in pDCs. Our data indicated that knockdown of mTOR or its downstream mediator p70S6K resulted in disruption of the MyD88-TLR9 interaction and nuclear localization of IRF7. Activation of mTOR enhances translation initiation in part by phosphorylation of its main targets, 4E-BP1, 4E-BP2, p70S6K1 and p70S6K2 (refs. 10-12,18) . Both 4E-BP1 and 4E-BP2 are translational repressors, and their phosphorylation by mTOR abrogates their ability to bind the initiation factor eIF4E and inhibit protein synthesis 32 . A study has shown that inhibiting expression of 4E-BP1 and 4E-BP2 enhances IRF7 translation and increases virus-stimulated interferon synthesis 23 .
Our study has indicated that in addition to the 4E-BP-dependent translational regulation of IRF7, activation of p70S6K leads to enhanced IRF7 phosphorylation and nuclear translocation. Together, the previous study 23 and our study here indicate that mTOR-mediated phosphorylation of 4E-BP1, 4E-BP2, p70S6K1 and p70S6K2 promotes IFN-a production through IRF7. Our results are consistent with a study reporting a crucial function for PI(3)K in nuclear translocation of IRF7 and production of type I interferon by human pDCs in response to TLR stimulation 33 , although the involvement of the 'downstream' mTOR pathway was not reported in that study.
The effect of rapamycin in blocking the association of TLR9 and MyD88 raises the issue of whether there is direct physical interaction between the mTOR complex and TLR9-MyD88. We were unable to obtain evidence of such an interaction by immunoprecipitation studies (data not shown). In addition, because TLR9-MyD88 interaction is a proximal event, it seems likely that rapamycin treatment would also inhibit other TLR9-mediated pathways, such as the transcription factor NF-kB pathway. Rapamycin treatment did indeed inhibit TLR9-mediated NF-kB signaling (data not shown), consistent with the lower production of proinflammatory cytokines such as TNF and IL-6. However, the lack of any effect on expression of CXCL10 or proteins such as CD86 may reflect incomplete blockage of the TLR9-MyD88 association by rapamycin.
Another issue is the extent to which the effects of rapamycin are specific to the TLR7-TLR9-MyD88-IRF7 axis in pDCs. To clarify the TLR specificity of mTOR inhibition, we examined IFN-a/b production by mouse splenic CD11c + DCs in response to various TLR ligands, as pDCs express only a limited set of TLRs. Rapamycin blocked IFN-a secretion in response to stimulation by ligands for TLR4, TLR7 and TLR9, but not in response to polyinosinic-polycytidylic acid (data not shown). TLR9 and TLR7 are thought to mediate all their effects through MyD88; in the case of LPS, the adaptor protein TRIF is believed to mediate the induction of IFN-b 34 . However, it is not clear whether TRIF is directly involved in the induction of IFN-a. In fact, it has been reported 25 that IFN-a is induced by LPS indirectly: TLR4 activation induces IFN-b through TRIF-IRF3, and this secreted IFN-b induces IRF7 activation, which then induces IFN-a. The effects of rapamycin on the induction of IFN-a in response to LPS can therefore be explained by the finding that knockdown of p70S6K1 and p70S6K2 inhibited IRF7 activation in our studies. In contrast, there was no inhibition of IFN-a production in response to stimulation with polyinosinic-polycytidylic acid (data not shown), which is known to induce type I interferons (IFN-a and IFN-b) through cytosolic helicase and RNA sensor MDA5-dependent signaling with the signaling adaptor IPS-1 (ref. 35) . We also noted that rapamycin inhibited IFN-a production in pDCs in response to modified vaccinia virus Ankara (data not shown). The mechanism of induction of IFN-a by this virus is thought to rely on both TLR-independent and TLR-dependent pathways 36 . Because this virus stimulates many receptors, including TLRs and non-TLRs, it is possible that mTOR also affects signaling through these non-TLRs. It is notable that we found Akt, mTOR and p70S6K, and, to a lesser extent, 4E-BP1, to be constitutively activated in pDCs in the steady state. One possible explanation for this is that pDCs are very sensitive to various stresses, including 'danger signals' from pathogen products 37 and changes in temperature and nutrients. In fact, the process of isolating DCs can cause them to become nonspecifically activated, as shown by the spontaneous upregulation of costimulatory molecules in cell culture in the absence of any exogenous stimulation 38 . Given the central function of mTOR in regulating cellular responses to fundamental changes in nutrients, growth factors and energy status, it is possible that the stresses involved in their isolation-induced activation of the mTOR pathway 39 . Immunoblot analysis showed that 'untouched' pDCs, isolated by depletion of other cell types from mouse spleen, had constitutively active mTOR (data not shown). Thus, constitutively phosphorylated mTOR in pDCs may represent a unique adaptation of these cells to facilitate rapid deployment of the type I interferon response against viral infection. In this context, it is notable that other such adaptations to facilitate rapid induction of type I interferons have been reported in pDCs. For example, the interferoninducing TLR9 ligand CpG-A is retained with the MyD88-IRF7 complex for long periods in the endosomal vesicles of pDCs 7 . In summary, our data show a function for mTOR in regulating TLRmediated activation of pDCs. Elements of the mTOR signaling pathway may thus represent potential therapeutic targets in the control of viral immunity and type I interferon-mediated diseases such as lupus 40 .
METHODS
